Startup Deep Dive : Pee Safe — from a bottle to a 6 million valuation

A toilet-seat spray that sold barely 100,000 bottles in its first three years went on to sell 1.7 million bottles after a single relaunch — and in January 2026 that same company, Pee Safe, pulled in $32 million (₹290 crore) from a healthcare-focused global investor.

The contradiction is the whole story: a category so awkward that most Indian brands would not touch it turned into a business that OrbiMed, which manages roughly $20 billion worldwide, chose to back at a valuation of close to ₹638 crore (about $66.5 million, at $1 ≈ ₹96.0 as of 18 September 2026, Trading Economics) — even while the company was still posting a loss.

Quick facts

What they do

Pee Safe makes and sells personal hygiene products for a market it argues nobody was building for seriously: the moment an Indian woman (or man) has to use a public toilet, manage a period, or deal with intimate care while stigma keeps the conversation off the table. It started with one product, a toilet seat sanitiser spray, and has since built out sanitary pads, menstrual cups, intimate washes, and travel hygiene kits under the Pee Safe brand, alongside newer sub-brands for grooming, sexual wellness, and nutraceuticals. It sells to individual consumers directly through its own website and marketplaces, through quick commerce apps, and through more than 50,000 physical retail points across over 100 Indian cities, with exports reaching about 23 countries.

The origin

The idea traces back to a single road trip. In 2013, Vikas Bagaria and his wife Srijana were travelling to Dwarka, Gujarat, when Srijana fell severely ill with a urinary tract infection after using a public washroom. UTIs are common and largely preventable, but almost nobody in India was selling a product to sanitise the part of a public toilet that actually touches skin, the seat itself. Bagaria was not a first-time founder: he had already run VR Forklift Marketing as managing director from 2000, founded SRV Damage Prevention in 2002, and started SafetyKart, an online safety-products portal, in 2012 after the Delhi gang-rape case that year had pushed personal safety into public conversation. The toilet-seat problem fit a pattern he already recognised: an everyday risk nobody had turned into a product. That road trip became the origin of what would later be spun out as Redcliffe Hygiene Private Limited.

The struggle years

The first version of the product was less a company than an experiment. From 2013, Bagaria spent close to three years testing the toilet seat sanitiser spray with friends, family, and a handful of small markets, refining the formulation and the pitch. The results were modest by any startup standard: across those three years, the venture sold roughly 100,000 bottles in total, a volume that would not sustain a real business, let alone attract institutional capital. There was no viral moment and no obvious channel; the product solved a real problem but the category was one nobody wanted to talk about, which made both marketing and retail listings harder than for an ordinary consumer good. The company needed outside capital to move past a hobby-scale operation, and it took until June 2017 for that capital to arrive, in the form of a pre-Series A round of about $1 million (around Rs 6.4 crore), reported at the time by Business Standard. That funding, not a change in the product itself, is what let Bagaria relaunch the business properly as “Pee Safe 2.0” under the newly formalised Redcliffe Hygiene Private Limited.

The turning point

The clearest before-and-after in Pee Safe’s history sits right at that 2017 relaunch. Before it: roughly 100,000 bottles sold over three years of testing, no formal retail distribution to speak of, and a single product. After it: more than 1.7 million bottles sold from 2017 onward, according to Pee Safe’s own retail interviews, alongside a rapid build-out into more than 15 products within a few years and, by the time of its October 2019 Series A, a presence in over 5,000 stores across 50 cities. The pre-Series A capital did not just extend the runway, it funded manufacturing scale-up, a proper retail sales effort, and enough marketing to convert the toilet-spray habit into a wider hygiene range. Every product added after 2017, from sanitary pads to intimate wash, rode on the trust the original spray had built rather than starting from zero.

The money behind it

Pee Safe has raised capital in stages rather than one dramatic round, and its total funding stands at about $45.55 million as of January 2026, per Entrepreneur India’s coverage of its most recent close.

• Pre-Series A, June 2017: about $1 million (Rs 6.4 crore), the round that funded the 2017 relaunch (Business Standard).
• Series A, announced 23 October 2019: Rs 30 crore led by Alkemi Growth Capital, earmarked for R&D, product development, and distribution (YourStory).
• Pre-Series B, June 2021: Rs 25 crore led by entrepreneur Shaival Desai alongside existing investor Alkemi Growth Capital, used for R&D and new product launches (Business Standard).
• Series C, announced 14 January 2026: $32 million (about Rs 290 crore) led by global healthcare investor OrbiMed, structured as a mix of fresh primary capital and a secondary sale that let some early backers partially cash out (Business Today, Entrackr).

The Series C is what moved Pee Safe’s ownership table the most. Venture Catalysts, which had backed the company since 2017, used the secondary component to exit entirely, booking a 9.60x return at a 30.53% XIRR, according to its own statement carried by Entrepreneur India and Outlook Business. Natco Pharma and Zerodha’s healthcare-focused arm, Rainmatter Health, are also named among current investors. The round valued Pee Safe at close to Rs 638 crore, up about 21.5% from a prior valuation of roughly Rs 525 crore, as reported by Indian Retailer and Entrepreneur India. OrbiMed also added two board members, Dr Sunny Sharma (its Asia senior managing director) and Sumona Chakraborty.

How it makes money

Pee Safe is a direct-manufacturer-to-consumer personal care business, not a marketplace, so there is no take rate: revenue is simply what customers and retail partners pay for physical product, sold across its own website, e-commerce marketplaces, quick commerce apps, and physical retail.

• Money in: product sales across toilet hygiene, feminine and intimate care, grooming (FURR), sexual wellness (Domina), and the newer nutraceuticals line (Within).
• Cost of materials: about Rs 27 crore in FY25, roughly 31% of total expenditure, up 29% year-on-year as volumes grew (Entrackr, citing RoC filings).
• Advertising and promotion: about Rs 26 crore in FY25, up 16% year-on-year, and still the single largest controllable cost after materials — a reminder that even nine years in, Pee Safe has to keep buying attention in a category people are reluctant to search for or discuss openly.
• Employee costs: about Rs 13 crore in FY25, up 18% year-on-year.
• Unit economics: the company spent Rs 1.05 for every Re 1 of revenue in FY25, an improvement from Rs 1.25 in FY24 — the gap that is closing, rather than any single high-margin line, is what is pulling Pee Safe toward breakeven.

The part most outsiders get wrong is treating Pee Safe as a single-SKU novelty brand built around one spray. In practice, the toilet spray is now a minority of the business: management has told trade press that FURR, its grooming sub-brand, is expected to contribute around 30% of FY27 revenue on its own, and the newly launched Within nutraceuticals line is projected to scale from about Rs 5 crore in FY27 to roughly Rs 100 crore within three years, per D2C Insider Pulse’s reporting on company targets. Those are company projections, not audited outcomes, and are labelled as such here.

The numbers

• FY24 revenue: Rs 56 crore, up from Rs 40.7 crore in FY23, per RoC filings cited by Dazeinfo and Entrackr (TheKredible’s independent read of the same filings puts the figure at Rs 57.26 crore, a rounding-level discrepancy between trackers rather than a disputed fact).
• FY25 revenue: Rs 82 crore, up 46% year-on-year (Entrackr, Dazeinfo).
• FY25 net loss: Rs 4 crore, down roughly 69-70% from a Rs 13 crore loss in FY24 (Entrackr, Indian Retailer).
• FY25 total expenses: Rs 86.5 crore, up 24% from about Rs 70 crore in FY24 (Entrackr).
• Balance sheet, FY25: current assets of about Rs 24 crore against cash and bank balances of just Rs 2 crore, a thin liquidity cushion recorded before the January 2026 Series C closed (Entrackr).
• Company-stated run rate: an annualised net revenue run rate exceeding Rs 150 crore as of the January 2026 funding announcement — a forward-looking figure, not an audited annual number (Business Today).

Where the money comes from

• Channel split: online channels (website, marketplaces, quick commerce) account for around 70% of revenue, with offline retail — general trade, modern trade, and pharmacies — making up the remaining 30%, per Indian Retailer’s D2C 100 coverage.
• Inside online: quick commerce alone makes up 35-40% of online sales, a channel that barely existed when Pee Safe launched its first product in 2017 (D2C Insider Pulse).
• Offline footprint: more than 50,000 retail outlets across over 100 Indian cities, with a stated ambition to expand toward 200,000 touchpoints (Indian Retailer, D2C Insider Pulse).
• Geography: exports to about 22-23 countries contributed roughly 8% of FY26 revenue, with a company target of 10-12% for FY27 (D2C Insider Pulse).
• The surprise: smaller cities such as Dehradun and Bhubaneswar have outperformed metro markets in retail terms, because entry barriers into local stores are lower and shop owners there behave more like entrepreneurial partners than gatekeepers, according to founder interviews carried by Afaqs.
• Category size: Pee Safe’s own market framing puts India’s female hygiene market at about Rs 1,700 crore, positioning its roughly Rs 150 crore run rate as a single-digit share of a market it argues is still under-served (Indian Retailer).

The risks

• Customer acquisition cost stays structurally high. Advertising and promotion consumed about Rs 26 crore in FY25, close to a third of revenue, because a stigma-adjacent category cannot rely on organic search or word-of-mouth alone to convert first-time buyers; the company itself has described converting one-time buyers into repeat customers as its central retention challenge, with only a fraction of first-time users becoming habitual purchasers, per Afaqs’ interview with the founder.
• Quick commerce dependency cuts into margin. With 35-40% of online sales now flowing through quick commerce apps, Pee Safe is exposed to those platforms’ listing fees, discounting expectations, and inventory-placement costs, a channel structure that did not exist for most of the company’s history and concentrates bargaining power with a handful of app operators (D2C Insider Pulse).
• Thin cash buffer ahead of the last raise. As of the FY25 balance sheet, Pee Safe held just Rs 2 crore in cash and bank balances against Rs 86.5 crore of annual expenses, a liquidity position that made the January 2026 fundraise more of a necessity than an option, and underlines how quickly a loss-making, ad-heavy D2C business can run through reserves between funding rounds (Entrackr).

The takeaway

Pee Safe’s real lesson is not about hygiene products at all: it is about what a founding product is actually for. The toilet seat spray never became a large business on its own, and three years of testing it in isolation nearly went nowhere. What changed the trajectory was using that one product to earn a specific kind of trust in an awkward category, and then treating every later launch, sanitary pads, intimate wash, grooming under FURR, nutraceuticals under Within, as a withdrawal against that trust rather than a fresh sales pitch. Founders chasing a single hero product often mistake the product for the asset. In Pee Safe’s case, the asset was always the willingness of a customer to buy something intimate from a brand once, come back a second time, and eventually let that brand follow them into other private categories.

Frequently asked questions

What does Pee Safe actually sell?

Pee Safe sells personal hygiene products: it started with a toilet seat sanitiser spray in 2017 and has expanded into sanitary pads, menstrual cups, intimate washes, travel hygiene kits, and, through newer sub-brands, grooming (FURR), sexual wellness (Domina), and women’s nutraceuticals (Within).

Who founded Pee Safe and when?

Vikas Bagaria conceived the idea in 2013 after his wife Srijana contracted a urinary tract infection from a public toilet during a road trip; the business was relaunched as “Pee Safe 2.0” under Redcliffe Hygiene Private Limited in 2017, with Srijana Bagaria and Rithish Kumar named as co-founders.

How much has Pee Safe raised, and at what valuation?

Pee Safe has raised about $45.55 million in total as of January 2026, across a 2017 pre-Series A, a 2019 Series A, a 2021 pre-Series B, and a $32 million Series C led by OrbiMed in January 2026, which valued the company at roughly Rs 638 crore, up from about Rs 525 crore.

Is Pee Safe profitable?

Not yet on a reported basis: it posted a net loss of Rs 4 crore in FY25 on revenue of Rs 82 crore, though that loss was down about 69% from Rs 13 crore in FY24, and the company has stated a target of profitability in FY27.

Does Pee Safe plan to go public?

The company has stated it is building toward an initial public offering in the FY29-30 window, alongside a target of roughly Rs 250 crore in revenue by FY27, according to its own comments to D2C Insider Pulse; both are forward targets rather than confirmed outcomes.

Sources

Figures are as of September 2026. Currency converted at $1 ≈ ₹96.0 as of 18 September 2026 (Trading Economics).

• Entrackr, “Pee Safe reports Rs 82 Cr revenue in FY25, nears breakeven,” September 2026
• Entrackr, “Pee Safe raises $32 Mn led by OrbiMed,” January 2026
• Dazeinfo (via X/Twitter), FY25 revenue and loss figures, September 2026
• TheKredible (via X/Twitter and blog), “Pee Safe Grows 40% to Rs 57.26 crore Revenue in FY24,” February 2026
• Business Today, “Pee Safe partners with OrbiMed to accelerate growth after $32 million Series C funding,” January 2026
• Entrepreneur India, “Women’s Hygiene Brand Pee Safe Secures USD 32 Mn from OrbiMed,” January 2026
• Entrepreneur India, “Venture Catalysts Exits Pee Safe with 9.60x Investment Gain,” January 2026
• Outlook Business, “Venture Catalysts Exits Pee Safe With 9.6X Returns After OrbiMed-Led Funding Round,” January 2026
• Indian Retailer, “Pee Safe Scales New Heights with Funding Boost and Investor Exit,” January 2026
• Indian Retailer / D2C Insider Pulse, “[D2C 100] Pee Safe Tapping into a Growing Rs 1,700 Cr Market”
• D2C Insider Pulse, “Pee Safe Targets Rs 250 Cr Revenue as It Builds Toward FY29-30 IPO,” 2026
• YourStory, “[Funding alert] Pee Safe raises Rs 30 Cr in Series A led by Alkemi Growth Capital,” October 2019
• Business Standard, “PeeSafe raises USD 1 mn in pre-Series A funding,” June 2017
• Business Standard, “Wellness startup Pee Safe raises Rs 25 cr for R&D, product launches,” June 2021
• Afaqs, “‘Want to be present in busy public toilets’: Vikas Bagaria, Pee Safe”
• Femtech Insider, “Pee Safe Raises $32 Million Series C to Scale Period and Personal Care Business in India,” January 2026

Found an error? Write to us and we’ll correct it in the open, dated, on the piece.